A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects with Advanced and/or Metastatic Hormone Receptor (HR)-positive, HER2-negative Breast Cancer
NOT ENROLLING
Trial ID:
NCT04505826 Protocol # :
21-137
Phase
I/II
Disease Sites
Breast
Principal Investigator
Lin, Nancy, U
Site Research Nurses
Campbell, Margaret
Caradonna, Lisa
Kasparian, Elizabeth
Patel, Nikita
Roche, Kathleen, A.
Rutter, Morgan
Trial Description
Call 877-DF-TRIAL (877-338-7425) to learn more about this clinical trial, protocol #21-137
21-137